A Pilot " Window-3 " Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Conditions: Lymphoma; Mantle Cell Lymphoma Interventions: Drug: Acalabrutinib; Drug: Rituximab; Other: Brexucabtagene Autoleucel; Drug: Cyclophosphamide; Drug: Fludarabine Phosphate Sponsors: M.D. Anderson Cancer Center; Kite, A Gilead Company; Acerta Pharma, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials